H.C. Wainwright lowered the firm’s price target on ImmunoPrecise Antibodies (IPA) to $7 from $9 and keeps a Buy rating on the shares following the fiscal Q2 report. Management laid out a strategy that allows for consolidating most of the company’s resources in one geo-economic region to focus on areas that seem very relevant to the drug discovery industry, the analyst tells investors in a research note. The firm says ImmunoPrecise is positioning itself for long-term growth.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPA:
- ImmunoPrecise Antibodies Reports Mixed Financial Results
- ImmunoPrecise Antibodies Reports Q2 Results and Strategic Advances in AI-Driven Drug Discovery
- ImmunoPrecise Antibodies Expands with Strategic Growth in Biologics and CRO Services
- ImmunoPrecise Antibodies reports Q2 EPS (9c) vs. (10c) last year
- IPA Earnings this Week: How Will it Perform?